In arterial occlusive disease autoantibodies against ETAR and AT1R correlate with each other but are not associated with classical cardiovascular risk factors;Autoantikö rpertiter gegen ETAR und AT1R korrelieren posi-tiv bei peripherer arterieller verschlußkrankheit, sind jedoch nicht mit dem vorliegen klassischer risikofaktoren assoziiert

Vasa - Journal of Vascular Diseases

Volumn 43, Issue 2, 2014, Pages 113-123

  Albert, Christian ^a   Von Schultzendorf, Marie ^a   Şalaru, Delia ^a,d   Halloul, Zuhir ^a   Dragun, Duska ^b   Heidecke, Harald ^c   Mertens, Peter Rene ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c CellTrend   (Germany)

^d GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Angiotensin II type 1 receptor; Autoantibodies; Cardiovascular risk profiles; Endothelin 1 type a receptor; Peripheral arterial disease

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; AUTOANTIBODY; C REACTIVE PROTEIN; CHOLESTEROL; ENDOTHELIN 1 TYPE A RECEPTOR; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; URIC ACID;

ADULT; AGED; ANGIOGRAPHY; ANTIBODY TITER; ARTICLE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; CORRELATION COEFFICIENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART INFARCTION; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREVALENCE; PROSPECTIVE STUDY; SEX DIFFERENCE;

1 TYPE A RECEPTOR; ANGIOTENSIN II TYPE 1 RECEPTOR; AUTOANTIBODIES; CARDIOVASCULAR RISK PROFILES; ENDOTHELIN; PERIPHERAL ARTERIAL DISEASE;

ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNITY, HUMORAL; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ENDOTHELIN A; RISK FACTORS;

EID: 84896276974     PISSN: 03011526     EISSN: None     Source Type: Journal    
DOI: 10.1024/0301-1526/a000337     Document Type: Article

References (49)

1. Diehm C, Schuster A, Allenberg JR, Darius H, Haberl R, Lange S, et al. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis. 2004 Jan; 172(1): 95-105.
2. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011 May; 473(7347): 317-25.
3. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011; 17(11): 1410-22.
4. Pawlak K, Mysliwiec M, Pawlak D. Oxidized LDL to autoantibod-ies against oxLDL ratio - the new biomarker associated with carotid atherosclerosis and cardiovascular complications in dialyzed patients. Atherosclerosis. 2012 Sep; 224(1): 252-7.
5. Szmitko PE, Wang C-H, Weisel RD, Almeida JR de, Anderson TJ, Verma S. New markers of inf am-mation and endothelial cell activation: Part I. Circulation. 2003 Oct; 108(16): 1917-23.
6. Szmitko PE, Wang C-H, Weisel RD, Jefries GA, Anderson TJ, Verma S. Biomarkers of vascular disease linking infammation to endothe-lial activation: Part II. Circulation. 2003 Oct; 108(17): 2041-8.
7. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. T e bimodal mortality pattern of systemic lupus erythematosus. Am J Med. 1976 Feb; 60(2): 221-5.
8. Petri M. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. Lupus. 2000; 9(3): 170-5.
9. Caligiuri G, Nicoletti A, Poirier B, Hansson GK. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest. 2002 Mar; 109(6): 745-53.
10. Major AS, Fazio S, Linton MF. B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice. Arterioscler Thromb Vasc Biol. 2002 Nov; 22(11): 1892-8.
11. Ait-Oufella H, Herbin O, Bouaziz J-D, Binder CJ, Uyttenhove C, Laurans L, et al. B cell depletion reduces the development of atherosclerosis in mice. J Exp Med. 2010 Aug; 207(8): 1579-87.
12. Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum. 2005 Aug; 35(1): 8-17.
13. Gonzalez-Juanatey C, Llorca J, Vazquez-Rodriguez TR, Diaz-Varela N, Garcia-Quiroga H, Gonzalez-Gay MA. Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy. Arthritis Rheum. 2008 Dec 15; 59(12): 1821-4.
14. Riemekasten G, Philippe A, Näther M, Slowinski T, Müller DN, Heidecke H, et al. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis. 2011 Mar; 70(3): 530-6.
15. Luf FC, Dechend R, Dragun D, Müller DN, Wallukat G. Agonistic antibodies directed at cell surface receptors and cardiovascular disease. J Am Soc Hypertens. 2008; 2(1): 8-14.
16. Dragun D, Philippe A, Catar R, Hegner B. Autoimmune mediated G-protein receptor activation in cardiovascular and renal pathologies. T romb Haemost. 2009 Apr; 101(4): 643-8.
17. Hiemann NE, Meyer R, Welln-hofer E, Schoenemann C, Heidecke H, Lachmann N, et al. Non-HLA Antibodies Targeting Vascular Receptors Enhance Alloimmune Response and Mi-crovasculopathy After Heart Transplantation. Transplantation [Internet]. 2012 Oct; Available from: http://dx.doi.org/10.1097/TP.0b013e3182692ad2
18. Yang BC, Phillips MI, Mohuczy D, Meng H, Shen L, Mehta P, et al. Increased angiotensin II type 1 receptor expression in hypercholes-terolemic atherosclerosis in rabbits. Arterioscler T romb Vasc Biol. 1998 Sep; 18(9): 1433-9.
19. Hansson GK. Immune mechanisms in atherosclerosis. Arterio-scler Thromb Vasc Biol. 2001 Dec; 21(12): 1876-90.
20. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997 Mar 1; 145(5): 408-15.
21. Haque S, Mirjafari H, Bruce IN. Atherosclerosis in rheumatoid arthritis and systemic lupus ery-thematosus. Curr Opin Lipidol. 2008 Aug; 19(4): 338-43.
22. Salmon JE, Roman MJ. Subclini-cal atherosclerosis in rheumatoid arthritis and systemic lupus ery-thematosus. Am J Med. 2008 Oct; 121(10 Suppl 1):S3-8.
23. Roux-Lombard P, Pagano S, Mon-tecucco F, Satta N, Vuilleumier N. Auto-antibodies as emergent prognostic markers and possible mediators of ischemic cardiovascular diseases. Clin Rev Allergy Immunol. 2013 Feb; 44(1): 84-97.
24. Matsuura E, Kobayashi K, Matsu-nami Y, Shen L, Quan N, Makarova M, et al. Autoimmunity, infectious immunity, and atherosclerosis. J Clin Immunol. 2009 Nov; 29(6): 714-21.
25. Greco TP, Conti-Kelly AM, Greco T Jr, Doyle R, Matsuura E, Anthony JR, et al. Newer antiphospholipid antibodies predict adverse out comes in patients with acute coro nary syndrome. Am J Clin Pathol. 2009 Oct; 132(4): 613-20.
26. Xu Q, Willeit J, Marosi M, Kleindi-enst R, Oberhollenzer F, Kiechl S, et al. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. Lancet. 1993 Jan 30; 341(8840): 255-9.
27. Zhu J, Quyyumi AA, Rott D, Csako G, Wu H, Halcox J, et al. Antibodies to human heat-shock protein 60 are associated with the presence and severity of coronary artery disease: evidence for an autoimmune component of atherogenesis. Circulation. 2001 Feb 27; 103(8): 1071-5.
28. Vuilleumier N, Reber G, James R, Burger D, de Moerloose P, Dayer J-M, et al. Presence of autoanti-bodies to apolipoprotein A-1 in patients with acute coronary syndrome further links autoimmunity to cardiovascular disease. J Autoim-mun. 2004 Dec; 23(4): 353-60.
29. Salonen JT, Ylä-Herttuala S, Ya-mamoto R, Butler S, Korpela H, Salonen R, et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 1992 Apr 11; 339(8798): 883-7.
30. Cugno M, Borghi MO, Lonati LM, Ghiadoni L, Gerosa M, Grossi C, et al. Patients with antiphospho-lipid syndrome display endothe-lial perturbation. J Autoimmun. 2010 Mar; 34(2): 105-10.
31. Dieudé M, Gillis M-A, T éorêt J-F, Torin E, Lajoie G, Levine JS, et al. Autoantibodies to heat shock protein 60 promote thrombus formation in a murine model of arterial thrombosis. J Thromb Haemost. 2009 Apr; 7(4): 710-9.
32. Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jüpner A, et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest. 1999 Apr; 103(7): 945-52.
33. Dragun D, Müller DN, Bräsen JH, Fritsche L, Nieminen-Kelhä M, Dechend R, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograf rejection. N Engl J Med. 2005 Feb; 352(6): 558-569.
34. Ruiz-Ortega M, Lorenzo O, Suzuki Y, Rupérez M, Egido J. Proinf am-matory actions of angiotensins. Curr Opin Nephrol Hypertens. 2001 May; 10(3): 321-9.
35. Hernández-Presa M, Bustos C, Ortego M, Tuñon J, Renedo G, Ruiz-Ortega M, et al. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoat-tractant protein-1 expression, and macrophage inf ltration in a rabbit model of early accelerated atherosclerosis. Circulation. 1997 Mar 18; 95(6): 1532-41.
36. Nickenig G, Sachinidis A, Mi-chaelsen F, Böhm M, Seewald S, Vetter H. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation. 1997 Jan 21; 95(2): 473-8.
37. Gross CM, Gerbaulet S, Quensel C, Krämer J, Mittelmeier H-O, Luf FC, et al. Angiotensin II type 1 receptor expression in human coronary arteries with variable degrees of atherosclerosis. Basic Res Car-diol. 2002 Jul; 97(4): 327-33.
38. Ohkita M, Tawa M, Kitada K, Mat-sumura Y. Pathophysiological roles of endothelin receptors in cardiovascular diseases. J Pharmacol Sci. 2012; 119(4): 302-13.
39. Brunner F, du Toit EF, Opie LH. Endothelin release during isch-aemia and reperfusion of isolated perfused rat hearts. J Mol Cell Cardiol. 1992 Nov; 24(11): 1291-305.
40. Hasdai D, Kornowski R, Battler A. Endothelin and myocardial ischemia. Cardiovasc Drugs T er. 1994 Aug; 8(4): 589-99.
41. Intengan HD, Schifrin EL. Vascular remodeling in hypertension: roles of apoptosis, infammation, and f brosis. Hypertension. 2001 Sep; 38(3 Pt 2): 581-7.
42. Callera GE, Montezano AC, Touyz RM, Zorn TMT, Carvalho MHC, Fortes ZB, et al. ETA receptor mediates altered leukocyte-endothe-lial cell interaction and adhesion molecules expression in DOCA-salt rats. Hypertension. 2004 Apr; 43(4): 872-9.
43. Shirai N, Naruko T, Ohsawa M, Ikura Y, Sugama Y, Hirayama M, et al. Expression of endothelin-con-verting enzyme, endothelin-1 and endothelin receptors at the site of percutaneous coronary intervention in humans. J Hypertens. 2006 Apr; 24(4): 711-21.
44. Kitada K, Yui N, Matsumoto C, Mori T, Ohkita M, Matsumura Y. Inhibition of endothelin ETB receptor system aggravates neo-intimal hyperplasia af er balloon injury of rat carotid artery. J Pharmacol Exp T er. 2009 Dec; 331(3): 998-1004.
45. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation. 2011 Feb 1; 123(4):e18-e209.
46. Rubtsov AV, Rubtsova K, Kappler J W, Marrack P. Genetic and hormonal factors in female-biased autoimmunity. Autoimmun Rev. 2010 May; 9(7): 494-8.
47. Akishita M, Kozaki K, Eto M, Yo-shizumi M, Ishikawa M, Toba K, et al. Estrogen attenuates endothe-lin-1 production by bovine endo-thelial cells via estrogen receptor. Biochem Biophys Res Commun. 1998 Oct 9; 251(1): 17-21.
48. Bilsel AS, Moini H, Tetik E, Ak-sungar F, Kaynak B, Ozer A. 17Beta-estradiol modulates en-dothelin-1 expression and release in human endothelial cells. Cardiovasc Res. 2000 Jun; 46(3): 579-84.
49. Profumo E, Franco MD, Buttari B, Masella R, Filesi C, Tosti ME, et al. Biomarkers of subclinical atherosclerosis in patients with autoimmune disorders. Mediators Inf amm. 2012; 2012: 503942.